Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options.
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
3 patients were enrolled in each of 3 study cohorts. There three cohorts were given
differing, incrementally larger doses of this phase I drug. The same safety measures are
being obtained on all patients. Efficacy measures were individualized as enrolllees do not
have the same underlying vascular anomaly. The study is structured to include a 24 month
drug-phase and a 24 month follow-up phase. The study is now closed to enrollment.
Phase:
Phase 1
Details
Lead Sponsor:
Boston Children's Hospital Boston Children’s Hospital